Dr. Choueiri on belzutifan/cabozantinib in clear cell renal cell carcinoma

News
Video

Toni K. Choueiri, MD, highlights data from the phase 2 LITESPARK-003 trial, which were presented at the 2023 ESMO Congress.

In this video, Toni K. Choueiri, MD, highlights data from the phase 2 LITESPARK-003 trial (NCT03634540) exploring belzutifan plus cabozantinib in patients with clear cell renal cell carcinoma (cRCC), which he presented at the 2023 European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain. Choueiri is a professor of medicine at Harvard Medical School and an attending physician, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts.

Video Transcript:

What we did in the study I presented in LITESPARK-003 is combining belzutifan with cabozatinib, a potent VEGF TKI. We had 2 cohorts. Cohort 1, [previously] untreated patients, response rates 70%. Toxicity manageable with dose interruption and dose reduction, especially of cabozantinib. Every patient out of the 50 had tumor shrinkage, and 70% had responses defined by RESIST. Cohort 2 previously treated patients up to 2 lines of therapy, as long as they have a PD-1 inhibitor [or] PDL-1 inhibitor. We saw a response rate whether 1-line or 2-line, whether immunotherapy only or immunotherapy plus VEGF, around 30% cohort confirmed responses by investigator assessment. There was a progression-free survival around 14 months. Again, same range of toxicity. Intriguing results. And the progression-free survival in cohort 1 was around 30 months.

So, proof of concept 1, we can combine both drugs. Second, this was taken to a phase 3 [trial] that finished accrual. And third, there is a significant [antitumor] activity. So certainly, belzutifan seems to play well at least with a TKI.

This transcription has been edited for clarity.

Related Videos
Peter N. Tsambarlis, MD, answers a question during a Zoom video interview
Illustration of Benign Prostatic Hyperplasia | Image Credit: © Judith - stock.adobe.com
Leonardo Kayat Bittencourt, MD, PhD, answers a question during a Zoom video interview
blur image background of corridor in hospital or clinic image | Image Credit @ whyframeshot - stock.adobe.com
Male and female surgeon performing surgery | Image Credit: © Georgii - stock.adobe.com
 Licensed   FILE #:  458906503  Preview Crop  Find Similar  Expand Image DIMENSIONS 8000 x 5333px FILE TYPE JPEG CATEGORY The Environment LICENSE TYPE Standard or Extended A lake in the shape of a recycling sign in the middle of untouched nature | Image Credit: © malp - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.